checkAd

    Biofrontera - Heiße Turnaround-Spekulation (Seite 722)

    eröffnet am 08.09.09 12:28:32 von
    neuester Beitrag 22.03.24 10:58:30 von
    Beiträge: 66.480
    ID: 1.152.884
    Aufrufe heute: 113
    Gesamt: 8.226.869
    Aktive User: 0

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    3,1100+804,86
    1,3400+109,70
    3,0100+84,66
    12,090+29,03
    4,2500+26,49
    WertpapierKursPerf. %
    1,8000-19,64
    0,7603-23,97
    5,3100-28,72
    2,0400-35,44
    3,5100-46,00

    Beitrag zu dieser Diskussion schreiben

     Durchsuchen
    • 1
    • 722
    • 6648

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 03.11.20 19:10:27
      Beitrag Nr. 59.270 ()
      Antwort auf Beitrag Nr.: 65.584.769 von edelupolino am 03.11.20 18:51:22Es zeigt einfach das ganze Dilemma!
      Der Kurs stand doch schon bei 6 Euro und höher.
      Den Hype an der Nasdaq hätte man auch nutzen können.

      Und nur Balaton die Schuld dafür zu geben, ist doch etwas zu billig. Ein wenig Verantwortung hat der Vorstand ja dann doch.

      Traurig ist einfach, dass die Tatsache, dass man Akne seit Jahren vor sich herschiebt, als ganz normal betrachtet wird. Was hier für eine Chance vertan wird. Wahrscheinlich wird sich in der Amtszeit bis Ende 2022 daran auch nichts mehr ändern. Einen Geldregen sehe ich nicht und die Ansprache an neue Investoren ist seit Jahren unterirdisch.

      Es braucht wohl frischen Wind, ansonsten bleiben wir auf der Stelle stehen.
      Biofrontera | 2,910 €
      Avatar
      schrieb am 03.11.20 19:08:26
      Beitrag Nr. 59.269 ()
      Antwort auf Beitrag Nr.: 65.584.208 von walle1fc am 03.11.20 18:09:05Böse Zungen könnten behaupten, es ist kein Geld da weil:

      - man sich teure Prozesse leistet
      - die Vergütungen des Aufsichtsrats erhöht wurden
      - Optionen finanziert werden müssen
      - Assets unter Wert weggegeben werden
      - Xepi erst aufwändig in die Spur gebracht werden muss
      .
      .
      .

      Wie gesagt, böse Zungen könnten das behaupten, ich nicht, mir liegt das fern, obwohl es schon naheliegend ist :p
      Biofrontera | 2,910 €
      Avatar
      schrieb am 03.11.20 18:51:22
      Beitrag Nr. 59.268 ()
      Antwort auf Beitrag Nr.: 65.584.208 von walle1fc am 03.11.20 18:09:05Das ist sehr schade :
      Tip : Kurs hochfahren und eine KE durchführen, die sich für Bio und uns lohnt.

      Chancen ewig liegen lassen bringt nur was für die Konkurrenz.
      Biofrontera | 2,910 €
      Avatar
      schrieb am 03.11.20 18:44:36
      Beitrag Nr. 59.267 ()
      Antwort auf Beitrag Nr.: 65.584.208 von walle1fc am 03.11.20 18:09:05Da könnten doch auch mal die Heidelberger Geld für zuschustern.

      Wenn sie schon weiterhin Geld für EPI verbrennen wollen.

      Gruß
      Paluru
      Biofrontera | 2,910 €
      Avatar
      schrieb am 03.11.20 18:09:05
      Beitrag Nr. 59.266 ()
      Antwort auf Beitrag Nr.: 65.582.390 von Schwabinho am 03.11.20 16:00:12Offizielle Aussage ist bzw. War dass kein Geld dafür da ist.
      Biofrontera | 2,910 €
      2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 03.11.20 17:59:48
      Beitrag Nr. 59.265 ()
      Moin moin
      Ich bin jetzt auch mit einer kleinen Position wieder mit dabei. Gruß Axel
      PS. Bei den Kursen muss man ja kaufen 😉
      Biofrontera | 2,910 €
      Avatar
      schrieb am 03.11.20 16:00:12
      Beitrag Nr. 59.264 ()
      Antwort auf Beitrag Nr.: 65.579.372 von harryzon am 03.11.20 12:02:04Genau deshalb stellen doch manche Aktionäre die Frage, warum man das Thema Akne nicht mehr pusht?
      Regelmäßige Erfolgsmeldungen aus Studien würden den off-label Einsatz von Ameluz bestimmt fördern, ohne dass man sich der illegalen Marketingmethoden bedienen muss.

      Zusätzlich würde ich mir dann auch wünschen, dass man die Indikationserweiterung auf Akne extrem beschleunigt.

      So steht es in den Präsentationen der letzten zwei Jahre! Aus meiner Sicht ein Unding!

      Im Juni 2020 stand in der Präsentation "Phase II in preparation"
      Im Januar 2020 stand in der Präsentation "Phase II in preparation"
      Im Juli 2019 stand in der Präsentation "Phase II in preparation"
      Im Oktober 2018 stand in der Präsentation "Phase II in preparation"
      Biofrontera | 2,920 €
      Avatar
      schrieb am 03.11.20 12:34:40
      Beitrag Nr. 59.263 ()
      Photodynamic Therapy Market: Innovative Photodynamic Devices Show the Way for Exponential Growth in Cancer Treatment
      Photodynamic Therapy Market: Innovative Photodynamic Devices Show the Way for Exponential Growth in Cancer Treatment
      Published: Apr 16, 2020

      Transparency Market Research (TMR) has published a new report on the photodynamic therapy market for the Forecast period of 2019 - 2027. According to the report, the global photodynamic therapy market was valued at ~US$ 3 Bn in 2018, and is projected to expand at a CAGR of ~17% from 2019 to 2027.

      Global Photodynamic Therapy Market: Key Insights

      Photodynamic therapy is a part of treatment that uses drugs and devices for the treatment of different chronic diseases such as cancer and malignant musculoskeletal tumors.
      Increase in the prevalence as well as incidence of cancer and skin diseases, growth in the number of surgeries, and approval of new biologics are major factors anticipated to drive the global photodynamic therapy market during the forecast period.
      According to the National Cancer Institute of the U.S., around 1,735,350 new cancer cases were diagnosed in the U.S. in 2018. It also stated that, there were 15.5 million cancer survivors in the country in 2016, and the number is projected to rise to 20.3 million by 2026.
      North America held a leading share of the global photodynamic therapy market in 2018, due to increase in the number of cancer cases and approvals for new photosensitizers by the U.S. Food & Drug Administration (FDA).
      In June 2017, Theralase Technologies Inc. was granted a patent for its anti-cancer compound technology by the U.S. Patent and Trademark Office (USPTO). The USPTO granted a patent titled as ‘Metal-based Thiophene Photodynamic Compounds and their Use.’
      The photodynamic therapy market in Asia Pacific is expected to expand at a high CAGR of ~18% from 2019 to 2027, due to surge in the number of patients with psoriasis and acne, and rise in the demand for innovative cosmetic therapies in India, China, and South Korea.
      Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php…

      Rise in Prevalence of Skin Diseases to Drive Global Photodynamic Therapy Market

      Rise in the prevalence of skin diseases, worldwide, is projected to drive the global photodynamic therapy market during the forecast period.
      Acne is considered one of the most common skin conditions in the U.S., which affects over 50 million people in the country every year. Its prevalence is known to be higher among women, affecting over 15% of the total population of adult women.
      Psoriasis is known to affect over 7.5 million people in the U.S. every year, with a higher rate of prevalence among people aged between 45 and 64 years.
      This significant rise in the prevalence of skin diseases and the economic burden of these diseases generate high demand for photodynamic therapy, which is a cost-effective option.
      Photosensitizers Drugs Dominate Global Photodynamic Therapy Market

      Increase in the number of clinical trials for the development of new photosensitizers, rise in the number of market players strengthening their research and development activities, and increase in expenditure on new drug development are various factors expected to drive the drugs segment during the forecast period.
      In September 2018, Health Canada approved the clinical trial application (CTA) filed by Theralase Technologies Inc., allowing clinical study evaluation of Theralase’s lead anti-cancer drug, i.e. TLD-1433.
      Request for Analysis of the COVID19 Impact on the Photodynamic Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php…

      Cancer the Most Prominent Application in Photodynamic Therapy Market

      In terms of application, the global photodynamic therapy market has been segmented into cancer, actinic keratosis (AK), psoriasis, acne, and others. The cancer segment is further categorized into basal cell carcinoma, non-small cell lung cancer, head & neck cancer, and others.
      The cancer segment accounted for a major share of the global market in 2018, and is likely to continue its dominance during the forecast period.
      Growth of the cancer segment can be attributed to increase in the incidence of various types of cancer, such as head & neck cancer, basal cell carcinoma, breast cancer, and lung cancer.
      According to the World Health Organization (WHO), in India, lung, breast, and stomach cancers accounted for nearly 5.9%, 14%, and 5% of the total cancer cases, respectively, in 2018.
      Leading players operating in the global photodynamic therapy market have received drug patents for their newly developed molecules, having potential use in the treatment of cancer. In October 2019, Theralase Technologies Inc. was granted a patent in Europe for its anti-cancer light-activated photodynamic compounds (PDCs).
      Hospitals a Promising End User of Global Photodynamic Therapy Market

      In terms of end user, the global photodynamic therapy market has been categorized into hospitals, cosmetics & dermatology clinics, cancer treatment centers, and others.
      The cosmetics & dermatology clinics segment is likely to gain significant market share by 2027. Growth of this segment can be attributed to surge in the demand for photodynamic therapy lasers for use in the treatment of skin conditions such as psoriasis and acne across the globe, and patient preference for treatment in hospitals.
      Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php…" target="_blank" rel="nofollow ugc noopener">https://www.transparencymarketresearch.com/sample/sample.php…

      North America to Dominate Global Photodynamic Therapy Market

      In terms of region, the global photodynamic therapy market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a leading share of the global photodynamic therapy market during the forecast period, owing to the presence of key players in the U.S., increase in the demand for new biologics for cancer treatment, high adoption of photodynamic therapy, and new product launches by market players.
      In January 2019, Biofrontera AG received approval from the U.S. Food and Drug Administration (FDA), and earlier, from the European Medicines Agency (EMA), for up-scaling of the batch size for the production of Ameluz to 35 kilograms from the previous 7 kilograms. Increase in the batch size enabled the company to improve its production capabilities, thereby meeting the increasing demand for drugs.
      Growth Strategies of Key Players

      Key players operating in the global photodynamic therapy market are Biofrontera AG, Theralase Technologies Inc., Lumibird, Quest PharmaTech Inc., Modulight, Inc., Galderma Laboratories L.P. (Nestlé), Sun Pharmaceutical Industries Ltd., and SUS Advancing Technology Co., Ltd.
      One of the major strategies adopted by prominent players operating in the global photodynamic therapy market is extensive R&D efforts for the development of new photosensitizers. This is coupled with geographical expansion, especially in countries such as China and Japan.
      In May 2019, Theralase Technologies Inc. received a notice of acceptance for photodynamic compounds from the Chinese Patent Office for PDCs.
      About Us

      Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

      Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

      TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.



      https://www.biospace.com/article/photodynamic-therapy-market…
      Biofrontera | 2,900 €
      Avatar
      schrieb am 03.11.20 12:22:33
      Beitrag Nr. 59.262 ()
      Balaton beabsichtigt auf jeden Fall erstmal, weiteres Geld in Epigenomics zu versenken:


      DGAP-Adhoc: Epigenomics AG: Kapitalherabsetzung und weitere Ermächtigung zur Ausgabe von Wandelschuldschreibungen mit Backstop-Investor geplant

      https://news.guidants.com/#!Artikel?id=8951168
      Biofrontera | 2,900 €
      Avatar
      schrieb am 03.11.20 12:02:04
      Beitrag Nr. 59.261 ()
      Ich finde die Wirksamkeit von Ameluz gegen Acne nach nur drei Behandlungen schon sehr
      beeindruckend.

      https://southsidedermatology.com/before-after-photos/general…

      Fuer mich ist und bleibt Biofrontera ein Tenbagger auf Sicht der nächsten 4-5 Jahre.

      Gruss
      harryzon
      Biofrontera | 2,855 €
      1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
      • 1
      • 722
      • 6648
       DurchsuchenBeitrag schreiben


      Investoren beobachten auch:

      WertpapierPerf. %
      +0,41
      -0,77
      +2,30
      0,00
      +0,03
      -1,06
      -1,88
      +4,42
      +0,47
      -23,86
      Biofrontera - Heiße Turnaround-Spekulation